Chronic News and Research

RSS

Ampio reports effects of Ampion in treating chronic pain caused by osteoarthritis of the knee

Ampio Pharmaceuticals, Inc. today announced three peer-review publications that report the multifaceted and synergistic effects of Ampion in the treatment of osteoarthritis in the knee.

9 Jun 2015

Apitope's ATX-F8-117 granted FDA Orphan Drug Designation for treatment of haemophilia A patients

Apitope, the drug discovery and development company focused on disease-modifying treatments that reinstate immune tolerance, announced today that pre-clinical product candidate ATX-F8-117 has been granted Orphan Drug Status by the US Food and Drug Administration for the prevention or treatment of inhibitors in haemophilia A patients with inhibitors or at the risk of producing inhibitors.

9 Jun 2015

Stemedica receives FDA's IND approval for itMSC Phase IIa clinical trial to treat Alzheimer's disease

Stemedica Cell Technologies, Inc. received the FDA's investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using its allogeneic stem-cell therapy to treat subjects with mild to moderate dementia due to Alzheimer's disease (AD), the sixth leading cause of death in the United States.

9 Jun 2015

People across the world are living longer but spending more time in ill health

People across the world are living longer but spending more time in ill health as rates of nonfatal diseases and injuries - including diabetes and hearing loss - decline more slowly than death rates, according to a new analysis of 301 diseases and injuries in 188 countries.

9 Jun 2015

Protective antibody response could be effective in preventing mother-to-child HIV transmission

How most babies are protected from acquiring HIV from their infected mothers has been a matter of scientific controversy.

9 Jun 2015

Ibrutinib shows promise in CLL/SLL

The addition of ibrutinib to bendamustine and rituximab significantly prolongs progression-free survival in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma, according to the HELIOS trial.

8 Jun 2015

Breathe NIOV System improves exercise duration among patients with chronic respiratory disease

Breathe Technologies, a developer and manufacturer of innovative medical technologies for patients with respiratory insufficiency diseases and neuromuscular diseases, announced new data today demonstrating that use of its Non-Invasive Open Ventilation (NIOV) System in pulmonary rehabilitation was associated with significant improvement in mean exercise duration change (approximately 63 percent) among patients with chronic respiratory disease.

8 Jun 2015

Celtaxsys closes $40M Series D financing and receives $5M CFFT grant to conduct CTX-4430 Phase 2 trial

Celtaxsys, Inc., a clinical stage drug development company focused on developing novel therapies for inflammatory diseases, today announced the successful completion of a $40M Series D financing led by Domain Partners VIII. Additional investors in the financing include Lumira Capital, RMI Partners, Masters Capital Management and the Georgia Research Alliance Venture Fund.

8 Jun 2015

New therapeutic target discovered for idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease for which as yet no causal therapy exists. It is, however, known that the lung interstitium - the connective tissue between the air sacs in the lower part of the lung - is affected.

8 Jun 2015

BioLineRx's BL-9020 antibody holds promise in treating Type 1 diabetes

Type 1 diabetes, which usually appears in children and adolescents, affects over 30 million people worldwide. Resulting from an auto-immune reaction that destroys the pancreatic beta cells that produce insulin, the disease leads to pathologically high levels of sugar in the blood and urine, resulting in high rates of morbidity and mortality. The current treatment for Type 1 diabetes is lifetime administration of insulin by injection.

8 Jun 2015

Daily sugar-sweetened beverage habit may increase NAFLD risk

A daily sugar-sweetened beverage habit may increase the risk for non-alcoholic fatty liver disease (NAFLD), researchers from the Jean Mayer USDA Human Nutrition Research Center on Aging (USDA HRNCA) at Tufts University report today in the Journal of Hepatology.

8 Jun 2015

GBD analysis shows over 95% of global population has health problems

Just one in 20 people worldwide (4·3%) had no health problems in 2013, with a third of the world's population (2·3 billion individuals) experiencing more than five ailments, according to a major new analysis from the Global Burden of Disease Study (GBD) 2013, published in The Lancet.

8 Jun 2015

AWMSG recommends Daklinza (daclatasvir) for treatment of adult patients with chronic HCV infection

The All Wales Medicines Strategy Group has recommended Daklinza (daclatasvir) for the treatment of adult patients with chronic hepatitis C virus (HCV) infection. The recommendation is specifically for patients with advanced liver disease, for whom treatment options can be limited.

5 Jun 2015

Medical experts call for accurate, standardized estrogen testing methods

Unreliable estrogen measurements have had a negative impact on the treatment of and research into many hormone-related cancers and chronic conditions. To improve patient care, a panel of medical experts has called for accurate, standardized estrogen testing methods in a statement published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

5 Jun 2015

Eating less late at night may help reduce effects of sleep deprivation

Eating less late at night may help curb the concentration and alertness deficits that accompany sleep deprivation, according to results of a new study from researchers at the Perelman School of Medicine at the University of Pennsylvania that will be presented at SLEEP 2015, the 29th annual meeting of the Associated Professional Sleep Societies LLC.

5 Jun 2015

Ibrutinib (IMBRUVICA) improves survival in treatment-naïve patients with chronic lymphocytic leukemia

Today, Pharmacyclics LLC, an AbbVie company, announced that ibrutinib (IMBRUVICA) improved progression-free survival (PFS; primary endpoint) and multiple secondary endpoints including overall survival (OS) and overall response rate (ORR) in treatment-naïve patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL, respectively) in the final analysis of the Phase III RESONATE™-2 (PCYC-1115) trial.

5 Jun 2015

Boston Scientific announces European launch of Precision Novi SCS System

Boston Scientific announces the European launch of the Precision Novi Spinal Cord Stimulator (SCS) System at the International Neuromodulation Society in Montreal, Canada. The 16-contact primary cell device has CE Mark for the treatment of chronic pain, and is the smallest high-capacity primary cell device currently available.

5 Jun 2015

Montefiore's School Health Program awarded $3 million grant to support teen pregnancy prevention initiative

Montefiore Health System announced today that its School Health Program received a $3 million grant from the Jerome L. Greene Foundation, which is dedicated to furthering the causes of education, the arts, health, and social justice. The generous pledge will support a new teen pregnancy prevention initiative in the Bronx, which has one of the highest rates of teen pregnancy in the nation.

5 Jun 2015

Cyberonics announces results for fourth quarter and fiscal year 2015

Cyberonics, Inc. today announced results for the fourth quarter and fiscal year ended April 24, 2015.

4 Jun 2015

Egalet announces top-line results from Egalet-002 study in moderate drinkers

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced top-line results from a randomized, four-way crossover alcohol-interaction study in healthy male and female moderate drinkers with Egalet-002, an abuse-deterrent, extended-release, oral oxycodone-based product in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.

4 Jun 2015

Chronic News and Research

Ampio reports effects of Ampion in treating chronic pain caused by osteoarthritis of the knee

Apitope's ATX-F8-117 granted FDA Orphan Drug Designation for treatment of haemophilia A patients

Stemedica receives FDA's IND approval for itMSC Phase IIa clinical trial to treat Alzheimer's disease

People across the world are living longer but spending more time in ill health

Protective antibody response could be effective in preventing mother-to-child HIV transmission

Ibrutinib shows promise in CLL/SLL

Breathe NIOV System improves exercise duration among patients with chronic respiratory disease

Celtaxsys closes $40M Series D financing and receives $5M CFFT grant to conduct CTX-4430 Phase 2 trial

New therapeutic target discovered for idiopathic pulmonary fibrosis

BioLineRx's BL-9020 antibody holds promise in treating Type 1 diabetes

Daily sugar-sweetened beverage habit may increase NAFLD risk

GBD analysis shows over 95% of global population has health problems

AWMSG recommends Daklinza (daclatasvir) for treatment of adult patients with chronic HCV infection

Medical experts call for accurate, standardized estrogen testing methods

Eating less late at night may help reduce effects of sleep deprivation

Ibrutinib (IMBRUVICA) improves survival in treatment-naïve patients with chronic lymphocytic leukemia

Boston Scientific announces European launch of Precision Novi SCS System

Montefiore's School Health Program awarded $3 million grant to support teen pregnancy prevention initiative

Cyberonics announces results for fourth quarter and fiscal year 2015

Egalet announces top-line results from Egalet-002 study in moderate drinkers

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News